Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. / Iversen, Helle Klingenberg; Olesen, J.

I: Cephalalgia : an international journal of headache, Bind 16, Nr. 6, 10.1996, s. 412-8.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Iversen, HK & Olesen, J 1996, 'Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs', Cephalalgia : an international journal of headache, bind 16, nr. 6, s. 412-8.

APA

Iversen, H. K., & Olesen, J. (1996). Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia : an international journal of headache, 16(6), 412-8.

Vancouver

Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia : an international journal of headache. 1996 okt.;16(6):412-8.

Author

Iversen, Helle Klingenberg ; Olesen, J. / Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. I: Cephalalgia : an international journal of headache. 1996 ; Bind 16, Nr. 6. s. 412-8.

Bibtex

@article{3b5e4946e2974f7c922dbe7d1d27915e,
title = "Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs",
abstract = "Experimental {"}vascular{"} headache in humans may be used in characterizing new migraine drugs. The effects of sumatriptan on nitroglycerin-(NTG)-induced headache and arterial responses were therefore studied. Following a double-blind randomized crossover design, 10 healthy volunteers received sumatriptan 6 mg s.c. or placebo succeeded by 20 min NTG (0.12 microgram/kg/min) infusion. Headache was rated on a 10 points scale. Temporal and radial artery diameters and velocity in the middle cerebral artery (MCA) were measured with ultrasound. Sumatriptan reduced the NTG-induced headache, median score 1.5 versus 4 after placebo (p < 0.01) and decreased temporal and radial artery diameters 75 +/- 3 and 86 +/- 3% of baseline respectively (p < 0.05). Blood velocity in the MCA was unaffected. The NTG model may prove to be a valuable tool in the development of future migraine drugs. The results suggest that NTG headache in non-migraineurs may share mechanisms with migraine headache.",
keywords = "Adult, Blood Flow Velocity, Brain, Cross-Over Studies, Double-Blind Method, Female, Headache, Humans, Male, Nitric Oxide, Nitric Oxide Synthase, Nitroglycerin, Sumatriptan, Vascular Resistance, Vasoconstrictor Agents, Vasodilator Agents",
author = "Iversen, {Helle Klingenberg} and J Olesen",
year = "1996",
month = oct,
language = "English",
volume = "16",
pages = "412--8",
journal = "Cephalalgia",
issn = "0800-1952",
publisher = "SAGE Publications",
number = "6",

}

RIS

TY - JOUR

T1 - Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs

AU - Iversen, Helle Klingenberg

AU - Olesen, J

PY - 1996/10

Y1 - 1996/10

N2 - Experimental "vascular" headache in humans may be used in characterizing new migraine drugs. The effects of sumatriptan on nitroglycerin-(NTG)-induced headache and arterial responses were therefore studied. Following a double-blind randomized crossover design, 10 healthy volunteers received sumatriptan 6 mg s.c. or placebo succeeded by 20 min NTG (0.12 microgram/kg/min) infusion. Headache was rated on a 10 points scale. Temporal and radial artery diameters and velocity in the middle cerebral artery (MCA) were measured with ultrasound. Sumatriptan reduced the NTG-induced headache, median score 1.5 versus 4 after placebo (p < 0.01) and decreased temporal and radial artery diameters 75 +/- 3 and 86 +/- 3% of baseline respectively (p < 0.05). Blood velocity in the MCA was unaffected. The NTG model may prove to be a valuable tool in the development of future migraine drugs. The results suggest that NTG headache in non-migraineurs may share mechanisms with migraine headache.

AB - Experimental "vascular" headache in humans may be used in characterizing new migraine drugs. The effects of sumatriptan on nitroglycerin-(NTG)-induced headache and arterial responses were therefore studied. Following a double-blind randomized crossover design, 10 healthy volunteers received sumatriptan 6 mg s.c. or placebo succeeded by 20 min NTG (0.12 microgram/kg/min) infusion. Headache was rated on a 10 points scale. Temporal and radial artery diameters and velocity in the middle cerebral artery (MCA) were measured with ultrasound. Sumatriptan reduced the NTG-induced headache, median score 1.5 versus 4 after placebo (p < 0.01) and decreased temporal and radial artery diameters 75 +/- 3 and 86 +/- 3% of baseline respectively (p < 0.05). Blood velocity in the MCA was unaffected. The NTG model may prove to be a valuable tool in the development of future migraine drugs. The results suggest that NTG headache in non-migraineurs may share mechanisms with migraine headache.

KW - Adult

KW - Blood Flow Velocity

KW - Brain

KW - Cross-Over Studies

KW - Double-Blind Method

KW - Female

KW - Headache

KW - Humans

KW - Male

KW - Nitric Oxide

KW - Nitric Oxide Synthase

KW - Nitroglycerin

KW - Sumatriptan

KW - Vascular Resistance

KW - Vasoconstrictor Agents

KW - Vasodilator Agents

M3 - Journal article

C2 - 8902249

VL - 16

SP - 412

EP - 418

JO - Cephalalgia

JF - Cephalalgia

SN - 0800-1952

IS - 6

ER -

ID: 128983912